Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

• Main Authors: George K.K. Lau, Teerha Piratvisuth, Xian Luo Kang, Patrick Marcellin, Satawat Thongsawat, Graham Cooksley, Edward Gane, Michael W. Fried, Cheng Chow Wan, Woon Paik Seung, Yu Chang Wen, Thomas Berg, Robert Flisiak, Philip McCloud, Nigel Pluck
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=21244447705&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/62382
• Institution: Chiang Mai University

BACKGROUND: Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen...